The cracks are inclined with respect to the c axis of MnAs, suggesting their initiation by a weak plane. For films thicker than about 2 mu m, the fracture extends to the substrates, where the in-plane crack angle

changes from about 57 degrees to around 45 degrees as the cracking is dictated by the cleavage plane of the substrates. Even for films much thinner than 0.5 mu m, annealing LY3023414 results in a delamination from substrate as a consequence of the large thermal expansion and, plausibly, the oxidation of MnAs. We show that Mn capping suppresses the delamination as well as the oxidation during the annealing.”
“Subjective cognitive side effects (CSEs) are common in patients taking antiepileptic drugs (AEDs). The objective of this Study was to predict which patients are at risk for CSEs, and compare the CSE profiles of all commonly used AEDs. In

this nomandomized retrospective study, medical records of 1694 adult outpatients with epilepsy seen at our center over a 5-year period who had taken one or more AEDs were examined. Non-AED predictors of CSEs were investigated, and rates of AED-related CSEs were compared in 1189 patients (546 on monotherapy) newly started on an AED at our center. The average rate of AED-related intolerable CSEs (leading to dosage PI3K inhibitor change or discontinuation) was 12.8%. On multivariate analysis, no significant non-AED predictors of CSEs were found. Significantly more intolerable CSEs were attributed to topiramate (21.5% of 130 patients) than to most other AEDs, including carbamazepine (9.9%), gabapentin (7.3%), PD0332991 in vitro levetiracetam (10.4%), lamotrigine (8.9%), oxcarbazepine (11.6%), and valproate (8.3%). CSE rates with zonisamide (14.9%) were significantly higher than those for gabapentin and lamotrigine. After exclusion of CSEs during the first 8 weeks of therapy, rates of CSEs were lower, but relative differences remained

unchanged. In monotherapy, significantly more intolerable CSEs occurred with topiramate (11.1% of 18 patients) than with carbamazepine or valproate, and both phenytoin and zonisamide were associated with more CSEs than valproate. From this study, it can be concluded that intolerable patient-reported CSEs are most common with topiramate, followed by zonisamide, phenytoin, and oxcarbazepine. They are least likely to be reported with gabapentin, valproate, lamotrigine, carbamazepine, and levetiracetam. (c) 2008 Elsevier Inc. All rights reserved.”
“P>Cardiac retransplantation represents the gold standard treatment for a failing cardiac graft but the decision to offer the patient a second chance is often made difficult by both lack of donors and the ethical issues involved. The aim of this study was to evaluate whether retransplantation is a reasonable option in case of early graft failure. Between November 1985 and June 2008, 922 patients underwent cardiac transplantation at our Institution.